Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

See Locations Near You

Summary

The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant has a history of RRMM, and must:

Part A: Have previously received ≥ 3 prior lines of anti-myeloma therapy.
Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.

Exclusion Criteria:

• Must not have previously received alnuctamab or mezigdomide.

Note: Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

156

Study ID:

NCT06163898

Recruitment Status:

Recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 21 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States More Info
Luciano Costa, Site 0033
Contact
205-934-9695
Local Institution - 0032
San Francisco California, 94143, United States More Info
Site 0032
Contact
Yale New Haven Hospital-Smilow Cancer Center
New Haven Connecticut, 06511, United States More Info
Noffar Bar, Site 0035
Contact
000-000-0000
Weill Cornell Medical College
New York New York, 10065, United States More Info
Ruben Niesvizky, Site 0018
Contact
646-258-0156
Local Institution - 0004
Aarhus Midtjylland, 8200, Denmark More Info
Site 0004
Contact
Local Institution - 0007
Odense Syddanmark, 5000, Denmark More Info
Site 0007
Contact
Local Institution - 0008
Lille Nord, 59000, France More Info
Site 0008
Contact
Local Institution - 0009
Nantes Pays-de-la-Loire, 44000, France More Info
Site 0009
Contact
Local Institution - 0027
Paris , 75010, France More Info
Site 0027
Contact
Local Institution - 0037
Essen Nordrhein-Westfalen, 45122, Germany More Info
Site 0037
Contact
Local Institution - 0036
Heidelberg , D-691, Germany More Info
Site 0036
Contact
Local Institution - 0038
Wuerzburg , 97080, Germany More Info
Site 0038
Contact
Rabin Medical Center
Petah-Tikva HaMerkaz, 49100, Israel More Info
Iuliana Vaxman, Site 0021
Contact
972547994003
Sheba Medical Center
Ramat Gan HaMerkaz, 52621, Israel More Info
Hila Magen, Site 0030
Contact
972504065462
Hadassah Medical Center
Jerusalem , 91120, Israel More Info
Moshe Gatt, Site 0020
Contact
97226779268
Local Institution - 0044
Rotterdam Zuid-Holland, 3015 , Netherlands More Info
Site 0044
Contact
Local Institution - 0029
Groningen , 9713 , Netherlands More Info
Site 0029
Contact
Local Institution - 0039
Málaga Andalucía, 29010, Spain More Info
Site 0039
Contact
Local Institution - 0023
Santander Cantabria, 39008, Spain More Info
Site 0023
Contact
Local Institution - 0025
Pamplona Navarra, 31008, Spain More Info
Site 0025
Contact
Local Institution - 0028
Salamanca , 37007, Spain More Info
Site 0028
Contact
Load More

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

156

Study ID:

NCT06163898

Recruitment Status:

Recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.